RT Crémieux: 現在最もエキサイティングな長寿トレンドは、認知症を実際に克服しつつあることです。70歳、75歳、80歳など、特定の年齢における認知症の有病率は、数十年前と比較して低下しています。
現在、特定の年齢（70歳、75歳、80歳など）における認知症の有病率は数十年前よりも低下しており、特に今日の90歳は1984年当時の90歳と比べて認知症リスクが半分以下になっています。これは長寿研究において最も有望な進展の一つです。
関連記事
The article examines the field of longevity research, focusing on Altos Labs and cellular rejuvenation. While acknowledging widespread hype around anti-aging breakthroughs, it details serious scientific work on biological reprogramming that could fundamentally extend human healthspan, distinguishing genuine advances from exaggerated claims.
The article examines the growing field of cellular rejuvenation research, particularly work at Altos Labs, which aims to reverse biological aging at the cellular level. While acknowledging that much longevity science is overhyped, it highlights that this line of research could fundamentally reshape medicine and human healthspan if it succeeds.
Researchers have discovered unexpected cancer-like mutations in the brain's immune cells that may contribute to Alzheimer's disease progression. These mutations occur in microglia cells and appear to drive inflammation and neurodegeneration. The findings suggest new potential therapeutic targets for Alzheimer's treatment.
The article explores the growing interest among wealthy and powerful individuals in longevity and life-extension technologies, examining the ethical and societal implications if such breakthroughs become accessible only to a select few.
The largest randomized controlled trial of rapamycin, a leading longevity drug, is currently underway. This human trial aims to provide evidence about the drug's potential effects on aging and lifespan.